The Academy of Managed Care Pharmacy (AMCP) issued the following statement from AMCP CEO Susan A. Cantrell, MHL, RPh, CAE, regarding President Trump’s new and proposed tariffs on U.S. imports from Canada, Mexico, and China: “Although President Trump’s new and proposed tariffs aim to level the playing field between American industries and our foreign competitors, we are concerned about the unintended, adverse consequences they may have on the cost of medicines in the U.S.

AMCP and its members advocate for bipartisan legislation that eliminates bureaucratic barriers to high-quality, innovative therapies, while lowering the bill footed by patients, families, government, employers, and other healthcare payers.

Hear from AMCP CEO Susan Cantrell about bringing accuracy to the public discourse on health care.

People with rare diseases often have mental health challenges related to their health care. These vary by disease, but there are common issues that make it difficult for individuals and their families, including delays in getting diagnosed, not knowing what will happen in the future, having limited treatments, and facing financial difficulties.

The AMCP Poster Abstract Program provides a forum for authors to share their research with the managed care pharmacy community.

View our Market Insights webinar that features a candid conversation with panelists from AMCP's Market Insights Roundtable on Optimizing the Management of Inherited Blood Disorders, Part 2 - a follow-up program to the 2022 Roundtable.

With President Trump and his administration returning to Washington, D.C., and a new Congress set to take shape, there’s naturally some uncertainty when it comes to the future of American health care policy. Looking ahead to 2025, however, there will likely be some key decisions affecting and defining how managed care pharmacy and the larger health care system operate and serve patients.